ASP 7713

Drug Profile

ASP 7713

Alternative Names: ASP7713

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bladder dysfunction

Most Recent Events

  • 07 Nov 2017 Astellas Pharma suspends patient enrolment in a phase I trial in Bladder dysfunction (In the elderly, In adults, In volunteers) due to management decision in United Kingdom (PO) (NCT03108755)
  • 30 Apr 2017 Phase-I clinical trials in Bladder dysfunction (In the elderly, In adults, In volunteers) in United Kingdom (PO) (Astellas Pharma pipeline, April 2017)
  • 06 Apr 2017 Astellas Pharma plans a phase I trial for an Undisclosed indication (In Adults, In elderly) in USA (NCT03108755)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top